Share on StockTwits

Conatus Pharmaceuticals (NASDAQ:CNAT) is scheduled to issue its Q214 quarterly earnings data on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 7.54 on Tuesday. Conatus Pharmaceuticals has a 52 week low of $5.06 and a 52 week high of $15.67. The stock has a 50-day moving average of $7.92 and a 200-day moving average of $8.25. The company’s market cap is $116.3 million.

On the ratings front, analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, June 13th. They set a “buy” rating and a $19.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $16.50.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.